Patents Assigned to Sunshine Lake Pharma Co., Ltd.
  • Publication number: 20200392146
    Abstract: Nitrogenous tricyclic compounds and uses thereof in medicine, in particular, a novel nitrogenous tricyclic compound used as an FXR active regulator and a stereoisomer, a geometrical isomer, a tautomer, a N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, and use of the compound in the manufacture of a drug for treating a disease and/or disorder regulated by FXR. A pharmaceutically acceptable composition containing the compound and a method of treating a disease and/or disorder mediated by FXR comprising administering the compound or pharmaceutical composition thereof.
    Type: Application
    Filed: January 28, 2019
    Publication date: December 17, 2020
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xinye YANG, Xiaojun WANG, Junwen WU, Hong CHEN, Shengtian CAO, Yingjun ZHANG
  • Publication number: 20200377461
    Abstract: An amine compound serving as a semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein-1 (VAP-1) inhibitor, a pharmaceutical composition, and an application thereof in medicines that can be used for treating inflammation and/or inflammation related diseases, diabetes and/or a disease related diabetes, psychiatric disorder, ischemic disease, vascular disease, fibrosis, or tissue transplant rejection.
    Type: Application
    Filed: December 28, 2018
    Publication date: December 3, 2020
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Zheng GU, Jianhao LI, Zheng LI, Weihua WANG, Haoxiong QIN, Xuli WANG, Jianyu LIU, Yingjun ZHANG
  • Patent number: 10851068
    Abstract: A method for preparing a pyrimidone compound and an important intermediate in which raw materials of the preparation method are cheap, the reaction condition of preparation method is mild, the preparation method is simple to operate, and is safe and controllable, has high total yield, and thus is suitable for industrial production.
    Type: Grant
    Filed: July 3, 2018
    Date of Patent: December 1, 2020
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Runfeng Lin, Xiaojun Wang, Jihua Lin, Liang Chen, Yingjun Zhang, Jiancun Zhang
  • Publication number: 20200339564
    Abstract: Provided herein is inhibitors of influenza virus replication and uses thereof. Specifically, provided herein a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.
    Type: Application
    Filed: January 4, 2018
    Publication date: October 29, 2020
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Qingyun REN, Changhua TANG, Junjun YIN, Kai YI, Yibo LEI, Yejun WANG, Yingjun ZHANG
  • Patent number: 10800734
    Abstract: Provided are compounds of formula (I), or a stereoisomer, mixture of stereoisomers, deuterated analog, tautomer, solvate or pharmaceutically acceptable salt thereof, compositions, method of making and uses thereof.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: October 13, 2020
    Assignee: Sunshine Lake Pharma Co., Ltd.
    Inventors: Bifei He, Yuping Fan, Huixiong Lu, Guangyuan Liu, Zhongqing Wang, Zhonghua Luo
  • Publication number: 20200299294
    Abstract: The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.
    Type: Application
    Filed: June 9, 2020
    Publication date: September 24, 2020
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun ZHANG, Qingyun REN, Changhua TANG, Xiaohong LIN, Junjun YIN, Kai YI
  • Publication number: 20200283445
    Abstract: A dihydropyrimidine compound and use as a medicament, especially application as a medicament used for treating and preventing hepatitis B, specifically, is a compound having Formula (I) or (Ia), or a stereisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein the variables of the formulas are as defined in the specification; and also includes the use of the compound having Formula (I) or (Ia), or an enantiomer, a diastereoisomer, a tautomer, a hydrate, a solvate, or a pharmaceutically acceptable salt thereof as a medicament, especially use as a medicament for treating and preventing hepatitis B.
    Type: Application
    Filed: October 17, 2018
    Publication date: September 10, 2020
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Xinchang LIU, Qingyun REN, Guanghua YAN, Siegfried GOLDMANN, Yingjun ZHANG
  • Publication number: 20200283454
    Abstract: Disclosed are a compound as shown in formula (I) as an influenza virus replication inhibitor and a preparation method therefor, a pharmaceutical composition comprising the compound and the use of the compound and pharmaceutical composition thereof in the treatment of influenza.
    Type: Application
    Filed: September 18, 2018
    Publication date: September 10, 2020
    Applicants: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Changhua TANG, Qingyun REN, Huichao LUO, Junjun YIN, Kai YI, Yibo LEI, Yejun WANG, Yingjun ZHANG
  • Publication number: 20200276196
    Abstract: A substituted pyrimidine piperazine compound and uses thereof, and a pharmaceutical composition containing the compound and uses thereof. Wherein the compound has Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof. The substituted pyrimidine piperazine compound and the pharmaceutical composition containing the compound can be used to inhibit 5-hydroxytryptamine reuptake and/or activate the 5-HT1A receptors. Also, a method of preparing such compounds and pharmaceutical compositions, and uses thereof in the treatment of central nervous system dysfunction.
    Type: Application
    Filed: September 21, 2018
    Publication date: September 3, 2020
    Applicants: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Chuanfei JIN, Wenhe ZHONG, Haiping LIANG, Yingjun ZHANG
  • Patent number: 10759812
    Abstract: The present invention relates to a thienopyrimidine derivative and use thereof in medicine, and also to a pharmaceutical composition containing the compound. The compound or pharmaceutical composition is used for inhibiting acetyl-CoA carboxylase (ACC). The present invention also relates to a method of preparing such compound and pharmaceutical composition, as well as their use in the treatment or prevention of diseases regulated by acetyl-CoA carboxylase in mammals, especially in humans.
    Type: Grant
    Filed: January 22, 2018
    Date of Patent: September 1, 2020
    Assignee: Sunshine Lake Pharma Co., Ltd.
    Inventors: Wanjun Tang, Xinye Yang, Zheng Gu, Chenlu Li, Zongyuan Zhang, Zhifu Wan, Xiaojun Wang, Yingjun Zhang
  • Patent number: 10751339
    Abstract: The invention relates to the preparation and use of new aminopyrimidine derivatives as drug candidates in free form or in pharmaceutically acceptable salt form and formulations thereof for the modulation of a disorder or disease which is mediated by the activity of the PI3K enzymes. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of disorders or diseases, such as disorders of immunity and inflammation in which PI3K enzymes play a role in leukocyte function, and hyperproliferative disorders associated with PI3K activity, including but not restricted to leukemias and solid tumors, in mammals, especially humans.
    Type: Grant
    Filed: January 18, 2019
    Date of Patent: August 25, 2020
    Assignees: SUNSHINE LAKE PHARMA CO., LTD., CALITOR SCIENCES, LLC
    Inventors: Ning Xi, Liang Wang, Xuejin Feng, Min Liao
  • Patent number: 10717732
    Abstract: The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: July 21, 2020
    Assignee: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Yingjun Zhang, Qingyun Ren, Changhua Tang, Xiaohong Lin, Junjun Yin, Kai Yi
  • Publication number: 20200222376
    Abstract: The present invention provides salts of pyrazolo[1,5-?]pyridine derivative and use thereof. The invention also relates to a pharmaceutically acceptable composition comprising such salts and a method of using the salts and the pharmaceutically acceptable composition to prevent or treat a proliferative disorder or pulmonary fibrosis in a patient.
    Type: Application
    Filed: December 15, 2018
    Publication date: July 16, 2020
    Applicants: Sunshine Lake Pharma Co., Ltd., Calitor Sciences, LLC
    Inventors: Ning Xi, Mingming Sun
  • Patent number: 10688090
    Abstract: Disclosed herein are inclusion complexes comprising vilazodone or a pharmaceutically acceptable salt thereof and an inclusion material, compositions and pharmaceutical formulations comprising the inclusion complexes, and methods for preparing the inclusion complexes, compositions or pharmaceutical formulations.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: June 23, 2020
    Assignee: Sunshine Lake Pharma Co., Ltd.
    Inventors: Shuiwang Feng, Xin Huang, Jinsong You, Fangfang Huang
  • Publication number: 20200113879
    Abstract: A fused tricyclic compound and use thereof as a medicament, in particular as a medicament for the treatment and/or prevention of hepatitis B. Specifically, a compound having Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, wherein each variate is as defined in specification. The compound also includes a Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof as a medicament, especially as a medicament for the treatment and/or prevention of hepatitis B.
    Type: Application
    Filed: June 2, 2018
    Publication date: April 16, 2020
    Applicants: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Xinchang LIU, Qingyun REN, Jianzhou HUANG, Zhimin XIONG, Jinfeng XIONG, You LI, Yang LIU, Zhifu ZOU, Guanghua YAN, Siegfried GOLDMANN, Yingjun ZHANG
  • Publication number: 20200085822
    Abstract: The invention provides a class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.
    Type: Application
    Filed: December 14, 2017
    Publication date: March 19, 2020
    Applicants: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Changhua TANG, Qingyun REN, Junjun YIN, Kai YI, Yibo LEI, Yejun WANG, Yingjun ZHANG
  • Publication number: 20200010472
    Abstract: A class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.
    Type: Application
    Filed: March 1, 2018
    Publication date: January 9, 2020
    Applicant: SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Changhua TANG, Qingyun REN, Junjun YIN, Kai YI, Yibo LEI, Yejun WANG, Yingjun ZHANG
  • Patent number: 10501444
    Abstract: The invention provides a novel class of compounds as inhibitors of influenza virus replication, preparation methods thereof, pharmaceutical compositions containing these compounds, and uses of these compounds and pharmaceutical compositions thereof in the treatment of influenza.
    Type: Grant
    Filed: August 15, 2017
    Date of Patent: December 10, 2019
    Assignees: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Qingyun Ren, Changhua Tang, Junjun Yin, Kai Yi, Yingjun Zhang
  • Publication number: 20190352311
    Abstract: The present invention relates to a thienopyrimidine derivative and use thereof in medicine, and also to a pharmaceutical composition containing the compound. The compound or pharmaceutical composition is used for inhibiting acetyl-CoA carboxylase (ACC). The present invention also relates to a method of preparing such compound and pharmaceutical composition, as well as their use in the treatment or prevention of diseases regulated by acetyl-CoA carboxylase in mammals, especially in humans.
    Type: Application
    Filed: January 22, 2018
    Publication date: November 21, 2019
    Applicants: SUNSHINE LAKE PHARMA CO., LTD., NORTH & SOUTH BROTHER PHARMACY INVESTMENT COMPANY LIMITED
    Inventors: Wanjun TANG, Xinye YANG, Zheng GU, Chenlu LI, Zongyuan ZHANG, Zhifu WAN, Xiaojun WANG, Yingjun ZHANG
  • Patent number: 10479753
    Abstract: The present invention relates to a sacubitril intermediate and a preparation method thereof. The sacubitril intermediate disclosed herein can be prepared by a deprotection reaction of a compound. In addition, the intermediate can be used as a raw material to synthesize sacubitril. The method disclosed herein has advantages of easily obtained raw materials, simple preparation process, low cost, environment friendly, and etc., which is very suitable for industrial production.
    Type: Grant
    Filed: August 26, 2018
    Date of Patent: November 19, 2019
    Assignee: SUNSHINE LAKE PHARMA CO., LTD
    Inventors: Lei Chen, Guodong Sun, Xiaodong Han, Shun Li, Jiebin Zeng, Zhongqing Wang, Zhonghua Luo